Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:138441853" >
Interplay between h...
Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-05-14
-
Oxford University Press (OUP),2018
Nummerbeteckningar
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:138441853
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:138441853URI
-
https://doi.org/10.1177/2047487318773384DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. In fact, low-density lipoprotein (LDL)-lowering drugs have anti-inflammatory effects. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) has shown that interleukin (IL)-1β blockade reduces the incidence of cardiovascular events in patients with previous myocardial infarction and C-reactive protein levels >2 mg/L. These data confirm the connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 inflammasome that leads to IL-1β activation. LDL-lowering drugs are the foundation of cardiovascular prevention. Now, the CANTOS trial demonstrates that combining them with IL-1β blockade further decreases the incidence of cardiovascular events. However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce cardiovascular risk as opposed to only one randomized trial of IL-1β blockade. In addition, IL-1β blockade has only been studied in patients with C-reactive protein >2 mg/L, while the benefit of LDL-lowering is not restricted to these patients. Also, lipid-lowering drugs are not harmful even at very low ranges of LDL, while anti-inflammatory therapies may confer a higher risk of developing fatal infections and sepsis. In the future, more clinical trials are needed to explore whether targeting other inflammatory molecules, both related and unrelated to the IL-1β pathway, reduces the cardiovascular risk. In this regard, the ongoing trials with methotrexate and colchicine may clarify whether the cardiovascular benefit of IL-1β blockade extends to other anti-inflammatory mechanisms. A positive result would represent a major change in the future treatment of atherosclerosis.
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Back, MKarolinska Institutet
(författare)
-
Badimon, L
(författare)
-
Bochaton-Piallat, ML
(författare)
-
Cariou, B
(författare)
-
Daemen, MJ
(författare)
-
Egido, J
(författare)
-
Evans, PC
(författare)
-
Francis, SE
(författare)
-
Ketelhuth, DFJKarolinska Institutet
(författare)
-
Lutgens, E
(författare)
-
Matter, CM
(författare)
-
Monaco, C
(författare)
-
Steffens, S
(författare)
-
Stroes, E
(författare)
-
Vindis, C
(författare)
-
Weber, C
(författare)
-
Hoefer, IE
(författare)
-
Karolinska Institutet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European journal of preventive cardiology: Oxford University Press (OUP)25:9, s. 948-9552047-48812047-4873
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Tunon, J
-
Back, M
-
Badimon, L
-
Bochaton-Piallat ...
-
Cariou, B
-
Daemen, MJ
-
visa fler...
-
Egido, J
-
Evans, PC
-
Francis, SE
-
Ketelhuth, DFJ
-
Lutgens, E
-
Matter, CM
-
Monaco, C
-
Steffens, S
-
Stroes, E
-
Vindis, C
-
Weber, C
-
Hoefer, IE
-
visa färre...
- Artiklar i publikationen
-
European journal ...
- Av lärosätet
-
Karolinska Institutet